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Abstract
Introduction—chemotherapy-related cognitive dysfunction (CRCD) is a growing problem due to 
rising cancer rates and increasing numbers of cancer survivors. upwards of 70% of ovarian cancer 
patients report cognitive-changes following treatment for their cancer.
Areas covered—the underlying mechanisms of CRCD are a subject of active research and 
debate. the initial insult may start with the diagnosis of cancer itself, both in the number of 
peripheral cytokines it produces but also in the psychological changes caused by stress and anxiety 
associated with the diagnosis. chemotherapy, in its ability to alter dna in the replication cycle, has 
been shown to damage neurons and their stem cell precursors.
Expert commentary—based on proposed mechanisms and advancements in other 
neuropsychological diseases, various pharmacologic and behavioral interventions have been 
demonstrated to show improvements in patient’s quality of life and in their perceived cognitive 
abilities and memory. further research is necessary to be able to determine when and how these 
cognitive changes occur, and if their multiple potential biological underpinnings can synergize 
toward deleterious cognitive effects. future therapies will include prevention strategies to avert 
CRCD’s effects on patients.
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1. Introduction
Modern therapeutics used in gynecologic cancer care has led to more women living long 
beyond their initial diagnoses and treatment periods [1]. While survivorship in this 
population is viewed as the final goal by both patients and physicians, many survivors now 
report a large array of treatment-related toxicities, which severely decrease their quality of 
life after cancer treatment is completed. The most affected quality-of-life domains in the 
surveillance period include changes in cognition (specifically learning and memory), 
genitourinary issues, sexual health, and psychological concerns of recurrence. Of significant 
concern to many of these women is chemotherapy-related cognitive dysfunction (CRCD) – 
in one study of ovarian cancer patients, nearly 70% reported cognitive dysfunction [2].
CRCD refers to what has been cited in some studies as chemobrain or chemofog. While it 
does infer to chemotherapy playing a role, as demonstrated in various in vivo and in vitro 
studies, it does not attribute all cognitive decline that women experience to chemotherapy 
alone. It does, however, recognize that chemotherapy does play a role in this decline that is 
still being further defined. CRCD can specifically affect survivors of gynecologic cancers 
because many are exposed to platinum-based therapy, specifically cisplatin, which has been 
shown to affect neurons both in in vitro and in vivo studies. Some of the mechanisms by 
which cisplatin effects hippocampal neurons include reducing dendritic branching and spine 
density as well as by causing mitochondrial DNA damage, the latter of which can lead to 
oxidative stress which is postulated to also play a role in this cognitive dysfunction [3,4]. 
The cognitive problems are also further worsened by the fact that some ovarian cancer 
patients, diagnosed before naturally occurring menopause, undergo oophorectomy which 
causes immediate surgically induced menopause [5].
There is sparse literature on CRCD, partly due to under-reporting. Clinicians seldom explore 
changes in cognition unless specifically raised by patients [6]. In gynecologic cancers, the 
most common neurological complaint is taxane-induced peripheral neuropathy [7]. 
However, other neurologic and psychiatric symptoms, less commonly reported, are still 
faced by many cancer survivors. These include, but are not limited to anxiety, depression, 
and fatigue – which also worsen the patient’s ability to process and retain new information. 
Furthermore, age-related cognitive decline can be a confounding variable when evaluating 
patients for CRCD. The presence of new or concomitant neurologic and psychiatric 
disorders can also confound symptoms reported by the patient that may be attributed to new 
cognitive disorders that are not related to concurrent chemotherapy treatments. Another 
factor that contributes to the general paucity of data in this field is the lack of uniformity in 
testing for CRCD. Despite this, although various cognitive assessments exist to test for 
cognitive decline before, during, and after treatment; however, studies have cited that despite 
performing at average levels on these assessments they do not correlate with patient’s own 
subjective experience while undergoing treatment of cancer. This limitation is thought to be 
due to lack of sensitivity of these assessments at detecting more subtle changes [8].
The objective of this review is to define CRCD, determine the scope of the problem, and 
discuss therapeutic interventions and prevention strategies for this significant quality-of-life 
issue in survivors of gynecologic cancers. In this undertaking, we recognize that quality of 
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life and cognition are two distinct entities and CRCD may affect quality of life. We caution 
that while some studies presented in this review report an increase in quality of life, they do 
not necessarily correlate with improvements in patient cognitive abilities. Although some of 
these studies did not demonstrate an improvement in that cognitive domain, the 
improvement in the patient-reported quality-of-life scales was deemed important enough to 
include highlighting their role on how patients subjectively feel with these interventions.
1.1. Defining the problem
Chemotherapy-related cognitive dysfunction (CRCD) refers to a patient’s experience of the 
variety of cognitive changes that occur during or after chemotherapy administration [9]. 
These changes include problems with memory, word-finding difficulties, decreased 
executive function, task organization, and lower information processing speed. These 
cognitive domains are not typically assessed prior to treatment to understand where most 
patients’ baselines lie. The inherent problems of assessing cognitive function before starting 
the cancer treatment includes both the time and logistics constraints to fully assess these 
symptoms before starting potentially curative treatment – as a full neuropsychological 
evaluation is both time and resource intensive and there is an inability to detect specific and 
discrete cognitive deficits using a short and easy-to-use instrument such as the standard 
mini-mental status examination (MMSE) [10]. Most gynecologic oncologists will fail to 
recognize that a neuropsychological problem may exist if the patient has no trouble 
comprehending the written consent for surgery or chemotherapy. The patient, herself, may 
fail to recognize whether the problem had a temporal relationship with the onset of 
chemotherapy initiation. However, assessing patient’s baseline cognitive function before 
initiating chemotherapy is of utmost importance, as the patients who have had less cognitive 
reserve to begin with, are likely more susceptible to CRCD [11]. Furthermore, symptoms of 
CRCD may be subtle, despite interfering with daily life [12], and understanding their 
complete spectrum demands additional investment of time and expertise. Often times, even 
when the changes are not subtle, they fail to be apparent on neuropsychological testing 
batteries, which were formulated and tested, in other patient populations with degenerative 
neurologic conditions.
In a cross-sectional study in ovarian cancer patients examining cognition in patients with 
ovarian cancer, this population of cancer patients was noted to have significant impairment. 
Although the study was limited by its cross-sectional nature, without the ability of 
examining whether these deficits existed at baseline, it did demonstrate that women who 
received both chemotherapy and radiation had a trend to score lower than the other women 
with ovarian cancer that completed the cognitive assessments [13]. In a prospective 
longitudinal Gynecologic Oncology Group (GOG) study of ovarian cancer patients using 
online cognitive tests as well as validated questionnaires assessing quality of life, patient 
perceptions of their own cognitions, neuropathy scale, and an anxiety and depression survey, 
at baseline only a subset of patients had evidence of cognitive impairment in one domain of 
the online testing. Interestingly, impairments in at least one domain were seen in 25% of 
patients in this population during chemotherapy with only 17% impairment at 6-month 
follow up. While this suggests that chemotherapy plays a role in impairment, a causal link 
cannot be drawn from these conclusions [14].
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One of the reasons why it is difficult to determine the scope of the problem caused by CRCD 
is because of its largely unknown mechanism. Additionally, some studies in cancer literature 
have demonstrated that cognitive impairments may exist at cancer diagnosis. One of the few 
studies exploring cognitive function in ovarian cancer patients noted that at baseline there 
were deficits in select types of cognitive skills – specifically in this study, deficits were noted 
in fine motor skills [15]. This study explored both quality-of-life questionnaires reporting 
patients’ subjective experiences and also took into account neuropsychological evaluation. 
No consensus however has been developed on what cognitive tests – subjective or objective 
– to use to determine baseline or posttreatment cognitive impairments.
Assessments ranging from patient-reported questionnaires through online-based cognitive 
tests have been used in the studies reporting cancer and CRCD in the literature. The 
Cognitive Function Scale of the European Organization of Research and Treatment of 
Cancer Quality of Life Questionnaire C30, The Questionnaire of Experienced Deficits of 
Attention, Perceived Cognition Questionnaire, Patient Assessment of Own Functioning 
Scale, and the Cognitive Failures Questionnaire. Of the cognitive tests that have been 
employed the Cog State is an interactive, web-based cognitive test that allows for faster 
assessment of cognition and this has been validated specifically for clinical trials. Other 
formal cognitive tests that exist include Web-Based Cognitive Stability Test, the traditional 
Mini Mental Status Exam, Cognitive Drug Research Computerized Cognitive Assessment, 
California Verbal Learning Test-II, the Wechsler Memory Scale and Wechsler Adult 
Intelligence Scale. Without the proper training for administering these tests or evaluating the 
results, the clinical value is greatly diminished, therefore we recommend formal consultation 
with a neurologist when new cognitive changes are detected by the clinician or reported by 
the patient. Additionally, the role of neurological imaging is crucial – it is imperative in the 
setting of focal neurologic deficits or symptoms and should be considered in patients with 
vague complaints, biomarker evidence of recurrence and no clear site of disease recurrence 
on traditional imaging which typically looks at the base of the skull through the middle 
thigh.
1.2. Underlying mechanisms
The mechanism behind CRCD is unknown. Theories exist behind the various factors that 
may lead to its development. There is some thought that the diagnosis of cancer alone can 
cause cognitive changes by virtue of the cytokines released and stress-related changes [12]. 
This has been demonstrated in research on colon cancer and brain cancer [16,17]. Other 
factors that may be contributing to cognitive decline in this population include anxiety, 
depression, and menopause [18].
Physiologically, models have demonstrated that chemotherapy induces neurologic injury, 
even in the absence of cancer, both at the level of neurons as well as neural stem cell 
precursors [19,20]. To discern the variety of effects chemotherapy can have on the brain, 
researchers have studied the various regions of the brain that are responsible for learning and 
memory. The hippocampus, for instance, has an important role in memory. It has been 
shown that epigenetic changes in the hippocampus and prefrontal cortex, by means of 
histone acetylation, have caused decreases in neural progenitor cell proliferation [21]. In 
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vitro, hippocampal neurons demonstrate dramatic effects when encountering cisplatin, a 
common therapy in gynecologic cancers. Not only do they show decreased dendritic spine 
density but also irreversible excitatory synapse damage [4]. Discussion regarding the effects 
of chemotherapy on anatomic regions of the brain cannot continue without understanding 
the role of growth factors such as brain-derived neutrophic factor (BDNF). Low BDNF 
levels have been associated with cisplatin treatment as well as with cognitive decline in other 
neuropsychological diseases [4,22–25]. Polymorphisms of BDNF have demonstrated 
decreased activation in the region of the hippocampus on functional MRI [26].
Another plausible location of where chemotherapy may be exerting detrimental effects is the 
frontal cortex. Imaging studies, again as above, have shown changes in this area associated 
with chemotherapy. However, these alterations could not attribute a cause-and-effect 
mechanism suggesting that chemotherapy is inducing changes in the frontal cortex. A small 
imaging study of breast cancer patients, remote from receiving chemotherapy (at least 5–10 
years prior to the study) used FDG PET CT scans to look at metabolic changes in various 
regions of the brain and noted decreased metabolism in the frontal cortex, basal ganglia, and 
cerebellum [27].
Increased cytokine production is a known effect of having cancer and its subsequent 
treatment. The role of cytokines in causing CRCD have been explored as well, with the 
specific cytokines implicated including IL-1, IL-6, IL-8, MCP-1, and TNF-α [28]. In 
patients diagnosed with cancer, cytokines can increase both with the diagnosis itself but also 
with chemotherapeutic intervention, and higher cytokine levels can be detected in the 
hippocampal structures [29]. The cytokine production surge is not uniform and varies among 
individuals even diagnosed with the same types of cancers receiving the same adjuvant 
therapies [12,30,31]. The direct results of chemotherapeutic regimens causing disruptions of 
the blood–brain barrier (BBB) and escalations in the peripheral production of cytokines 
(likely caused by stress and cellular injury) are profound alterations on the neuronal survival 
and plasticity [3,32]. Oxidative stress and mitochondrial damage are other proposed 
mechanisms by which neuronal and neural stem cell damage occurs ultimately leading to 
CRCD [4]. Last, epigenetic changes may cause chronic problems due to upregulation of 
DNA-altering genes that lead to a cascade of long-lasting neurocognitive changes [12]. All 
these theories are important due to the fact that the mechanisms behind the neuronal changes 
can become valuable targets for pharmacologic interventions. Some interventions already 
exist; others will include novel strategies that have yet to be discovered. Studies examining 
the underlying mechanisms that may be contributing to CRCD as well as highlights from 
studies specifically in a gynecologic cancer population are displayed in Table 1.
2. Methodology
In exploring the literature to query studies that have been done on this topic, we looked at 
clinical trials, case series, and literary reviews from 1995 to 2017. Search terms used to 
garner results including ‘chemobrain, chemotherapy-induced cognitive changes, or 
chemofog.’ With the added term of gynecologic cancer, the search was extremely limited 
likely demonstrating the lack of research specifically in this population. Because of the 
limited amount of clinical trials, the filter of clinical trials was removed and more specific 
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filter criteria were placed in the database. These included the addition of filters looking 
specifically at imaging-related changes, studies that tested pretreatment cognition and last 
pharmacologic and behavioral interventions. It was in using that search criteria as well as in 
reviewing published work through gynecologic and neurologic literature addressing CRCD 
that the studies presented in this review were selected. Summaries of the various studies are 
seen in Tables 1 and 2 but are also included in context below..
2.1. Chemobrain in other cancer types and the potential effects of maintenance therapy
Although this discussion is mostly in the setting of gynecologic cancers, research in CRCD 
has been done and varies between cancer groups. For example, in research on recurrent 
glioblastoma, cognitive function tended to decline throughout the course of treatment. 
Patients treated for hematologic malignancies, patients receiving full-intensity high-dose 
stem-cell transplant HD-SCT were at higher risk, especially in women compared to men. 
This change was attributed to shortened telomere length [33]. The experience in colorectal 
cancer is quite unique in that cognitive dysfunction was seen through the course of their 
treatment regardless of whether they received chemotherapy [17]. This suggests the presence 
of cancer may in and of itself predispose individuals to cognitive decline regardless of their 
adjuvant therapies. Last, childhood cancers present a specific dilemma because of their 
administration of chemotherapy during a time when neural development is very high. In a 
study of Acute Lymphoblastic Leukemia, nonverbal learning was affected by chemotherapy, 
specifically in girls [34].
Patients with gynecologic malignancies, specifically recurrent ovarian and advanced cervical 
cancer are being treated with bevacizumab (Avastin), a monoclonal antibody that inhibits 
vascular endothelial growth factor A [35,36]. Data showing its benefits and its good safety 
profile has made it a valuable option for many patients. Besides its use in these gynecologic 
cancers, bevacizumab is commonly used as adjuvant or maintenance therapy in other 
cancers. MRI imaging studies in patients receiving it for malignant gliomas have shown 
significant and progressive hippocampal atrophy, potentially more severe than in patients 
with Alzheimer’s disease, specifically during the point in their treatment where they were 
only receiving bevacizumab. This was quite profound considering they demonstrated no 
statistically significant change during their chemoradiation and adjuvant temozolomide and 
these changes were only seen with bevacizumab alone [37]. No similar study in gynecologic 
cancer patients on bevacizumab has been done.
3. Interventions
3.1. Pharmacologic interventions
Many interventions have been proposed and trialed however few have provided substantive 
results. However, there have been a few behavioral and pharmacologic interventions 
specifically targeting the various proposed mechanisms and demonstrating interesting 
results. Most of these therapies have been drawn from research on other neuropsychological 
diseases where different interventions have been shown to be useful.
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Donepezil, a reversible acetylcholinesterase inhibitor, which has been used to treat 
Alzheimer’s disease, has also been shown to improve multiple areas of cognition in brain 
tumor patients. This open-label, phase II study also found that not only did it improve 
cognition but also quality of life and mood [38]. There has also been considerable research 
with Modafinil, a centrally acting drug that has been used for narcolepsy, major depressive 
disorder, and obstructive sleep apnea [38]. In breast cancer patients, it has been shown to 
improve cognitive performance and attention [43]. These have been shown in phase III 
randomized controlled trials, both open label and blinded. Similar results have been shown 
with the use of methylphenidate in brain cancer patients and children with brain tumors or 
acute lymphocytic leukemia [44]. New pharmacologic agents already in the clinical practice 
for other conditions – such as HDAC inhibitors and S-adenosyl methionine (SAM) – may 
prove to be novel therapies to prevent epigenetic changes in the genome leading to 
chemotherapy [45]. Determining the timing of these future therapies in order to prevent 
CRCD without decreasing the efficacy of the cancer drugs is of utmost importance [46]. 
These and several other studies showing similar results are summarized in Table 2.
3.2. Behavioral interventions
Behavioral interventions such as relaxation were shown to improve quality of life but not to 
improve cognition. Studies in breast cancer patients have shown that cognitive-behavioral 
therapy improved patient’s quality-of-life scores, although data regarding how its benefit on 
cognition and cognitive complaints has not been consistent among studies [47,60]. 
Occupational and speech therapy have demonstrated important roles however, mostly in the 
rehabilitative state, not in preventing future deficits [48–51]. Internationally, research on 
both short- and long-term yoga practices has demonstrated beneficial results in breast cancer 
patients treated with chemotherapy during treatment and months after treatment has 
completed [52–58]. These yoga studies show promising results in randomized-controlled 
trials [57]. Additionally, acupuncture has demonstrated positive effects on both memory and 
brain structures in Alzheimer Disease Patients, which were quantified using functional MRI 
[54], and could be trialed in the future for the CRCD patients. The pharmacologic and 
behavioral interventions have been summarized in Table 2.
Addressing CRCD would not only improve the quality of life in many cancer survivors, but 
would also increase their compliance with their cancer therapy. These studies, in addition to 
our own clinical experience, suggest that CRCD has tremendous quality-of-life implications 
in survivors of gynecologic cancers. This review also demonstrates that, not only is research 
in this field limited but it also underrepresents women diagnosed with gynecologic cancers 
[59]. Future research with models specifically examining this population is warranted.
4. Conclusion
This review has attempted to bring light to a condition that still does not have a definitive, 
scientifically proven etiology, and for which treatment options are very limited. CRCD may 
have many different causes. It can affect patients with certain cancers more than others. In 
the gynecologic population it is extremely important to address CRCD, as is potentially 
becoming more common and severe due to the use of neurotoxic drugs such as cisplatin and 
Pearre and Bota Page 7
Expert Rev Qual Life Cancer Care. Author manuscript; available in PMC 2019 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
other platinum-based compounds, to the advancing age of the population affected, and to the 
surgical menopause induced by life-saving cancer surgery. Studies specifically in ovarian 
cancer patients demonstrate that although there is an element of cognitive dysfunction, 
which is seen in this population at baseline, it can be precipitated by cancer-related treatment 
especially in an aging population [61]. As seen in the literature presented in this review, 
some cognitive dysfunction does exist at baseline in ovarian cancer patients. Although the 
term sometimes used by patients and even cited in some studies is chemobrain or chemofog, 
this misnomer seems to attribute all cognitive dysfunction experienced by a patient to 
chemotherapy. However, the term we have chosen to use in this review was CRCD because 
of the potential role that active chemotherapy does play in cognitive decline.
5. Expert commentary
Bringing light to this subject, we sought to examine why there are weaknesses in clinical 
management of CRCD and what they can be attributed to. Initial management of patients 
from diagnosis onwards focuses heavily on the cancer itself and the treatments necessary to 
cure it. Clinical management is focused on that because, in a sense, it has to in order to 
maximize a patient’s time and energy and a physician’s resources. Adding a neurocognitive 
assessment, even in its simplest form, can shift the focus away from assessing signs or 
symptoms of the cancer itself. This limits a provider from determining if cognitive deficits 
exist at baseline or even if there has been a marked change from baseline (a patient’s state 
prior to her cancer diagnosis) to the patient’s current state since learning she has a new 
cancer diagnosis. Its subtle changes on neurocognitive assessments also make diagnosing 
cancer-related cognitive decline difficult to quantify and compare. Ultimately when CRCD 
is noted, another weakness in its management is attributing it as a real entity related to 
cancer-treatment and not just age-related decline and potentially delaying treatment. 
Furthermore, without completely consistent results among both pharmacologic and 
behavioral interventions, even when CRCD is caught early and treatment is sought, it is 
difficult to prescribe a perfect regiment for each patient.
The major areas of growth in this field appear in two realms – the laboratory and the 
bedside. The laboratory seeks to find the underlying mechanisms of CRCD both in vitro and 
animal models. It attempts to delineate when, in the whole process, does CRCD occur and 
how much of a role the actual ‘cancer’ plays in all of it. When these can be determined, 
attempting to test currently available, FDA-approved therapies may be the next frontier in 
getting therapies from the lab to the patient in a safe and quick manner. With much focus 
placed on new therapies focused on the therapeutic roles of cytotoxic therapies, 
immunotherapies, and checkpoint inhibitors, basic science research has been lacking in 
finding the mechanisms behind some of the quality-of-life issues, like CRCD, patients 
exhibit. Continued assessment of patients’ quality-of-life concerns and dedication to 
research specifically examining the biologic underpinnings of these concerns will bring us 
close to finding the mechanism behind CRCD and eventually cure or even prevent it.
Although various mechanisms have been proposed and presented in this review, a very 
exciting new realm of research examines how epigenetic changes may be causing 
neurotoxicity and symptoms of CRCD. This brings in histone deacetylase (HDAC) 
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inhibitors to play as potential therapeutic interventions. This is an area of exciting research 
that may prove to be an exciting frontier in this field.
Given as the current research on interventions for CRCD, this treatment-related toxicity will 
not have one easy solution. It will most probably require multiple levels of involvement 
through the continuum of care, including early recognition by the practitioners administering 
the chemotherapy, and a multi-disciplinary management teams (including neurologists and 
neuropsychologists) which will focus on addressing patient’s concerns and actively 
promoting treatments that will potentially prevent or undo the harm that chemotherapy-may 
cause, while maintaining the patients on life-saving therapies and improving the quality of 
patient’s survival.
6. Five-year view
This review summarized the current state of the science, bringing up the various mechanisms 
proposed for CRCD, challenges in its assessment both pre- and posttreatment, and 
interventions that have been studied to improve CRCD and optimize a patient’s quality of 
life. Our vision in the next five years is that the strides made in determining the causes of 
CRCD became clear. Uncovering these mechanisms will allow for more directed trials of 
interventions to combat its effects. If, in finding the mechanism, it is discovered that an 
FDA-approved therapy does not already exist, it allows for newly developed targeted 
therapies to be used as an adjunct to neurotoxic chemotherapeutic regimens in women who 
are at risk of developing CRCD. We also hope that in bringing light to this issue, an 
intentional effort is put forth by clinicians to address quality-of-life concerns, such as 
CRCD, that patients may not always know to bring up.
References
Papers of special note have been highlighted as either of interest (•) or of considerable 
interest (••) to readers.
1. American Cancer Society. Global cancer facts & figures 2016. Am Cancer Soc. 2016:1–72.
2•. Stavraka C, Ford A, Ghaem-Maghami S, et al. A study of symptoms described by ovarian cancer 
survivors. Gynecol Oncol. 2017; 125:59–64. DOI: 10.1016/j.ygyno.2011.12.421
3•. Andres AL, Gong X, Di K, et al. Low-doses of cisplatin injure hippocampal synapses: a 
mechanism for “ chemo ” brain? Exp Neurol. 2014; 255:137–144. DOI: 10.1016/j.expneurol.
2014.02.020 [PubMed: 24594220] 
4•. Lomeli N, Di K, Czerniawski J, et al. Cisplatin-induced mitochondrial dysfunction is associated 
with impaired cognitive function in rats. Free Radic Biol Med. 2017; 102:274–286. DOI: 
10.1016/j.freeradbiomed.2016.11.046 [PubMed: 27908784] 
5. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: A 2014 update. Mol 
Cell Endocrinol. 2014; 389:7–12. [PubMed: 24508665] 
6. Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an 
international perspective from the Venice cognitive workshop. Ann Oncol. 2008; 19:623–629. 
[PubMed: 17974553] 
7. Wang X-M, Lehky TJ. Discovering cytokines as targets for chemotherapy-induced painful 
peripheral neuropathy. Cytokine. 2012; 59:3–9. [PubMed: 22537849] 
8. Hermelink K, Küchenhoff H, Untch M, et al. Two different sides of “chemobrain”: determinants and 
nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multi-center 
study. Psychooncology. 2010; 19:1321–1328. [PubMed: 20127909] 
Pearre and Bota Page 9
Expert Rev Qual Life Cancer Care. Author manuscript; available in PMC 2019 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. Berger, AM, Shuster, JL, Von Roenn, JH. Principles and practice of palliative care and supportive 
oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. 
10. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning 
in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003; 21:3557–3558. [PubMed: 
12913103] 
11. Lange M, Rigal O, Clarisse B, et al. Cognitive dysfunctions in elderly cancer patients: a new 
challenge for oncologists. Cancer Treat Rev. 2014; 40:810–817. [PubMed: 24713425] 
12•. Wang XM, Walitt B, Saligan L, et al. Chemobrain: a critical review and causal hypothesis of link 
between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015; 
72:86–96. DOI: 10.1016/j.cyto.2014.12.006 [PubMed: 25573802] 
13. Van Arsdale A, Rosenbaum D, Kaur G, et al. Prevalence and factors associated with cognitive 
deficit in women with gynecologic malignancies. Gynecol Oncol. 2016; 141:323–328. [PubMed: 
26946094] 
14••. Hess LM, Huang HQ, Hanlon AL, et al. Cognitive function during and six months following 
chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an 
NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015; 139:541–545. DOI: 
10.1016/j.ygyno.2015.10.003 [PubMed: 26456812] 
15••. Correa DD, Zhou Q, Thaler HT, et al. Cognitive functions in long-term survivors of ovarian 
cancer. Gynecol Oncol. 2010; 119:366–369. DOI: 10.1016/j.ygyno.2010.06.023 [PubMed: 
20630576] 
16. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment–associated cognitive change: an 
update on the state of the science. J Clin Oncol. 2012; 30:3675–3686. [PubMed: 23008308] 
17•. Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who 
do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 
2015; 33:4085–4092. DOI: 10.1200/JCO.2015.63.0905 [PubMed: 26527785] 
18. Minton O, Stone PC. A comparison of cognitive function, sleep and activity levels in disease-free 
breast cancer patients with or without cancer-related fatigue syndrome. BMJ Support Palliat Care. 
2012; 2:231–238.
19. Reiriz AB, Reolon GK, Preissler T, et al. Cancer chemotherapy and cognitive function in rodent 
models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res. 2006; 
12:5000–5001. [PubMed: 16914590] 
20. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of 
chemotherapeutic agents in vitro and in vivo. J Biol. 2006; 5:22. [PubMed: 17125495] 
21•. Briones TL, Woods J. Chemotherapy-induced cognitive impairment is associated with decreases 
in cell proliferation and histone modifications. BMC Neurosci. 2011; 12:124.doi: 
10.1186/1471-2202-12-124 [PubMed: 22152030] 
22. Zhang XY, Chen DC, Xiu MH, et al. Cognitive and serum BDNF correlates of BDNF Val66Met 
gene polymorphism in patients with schizophrenia and normal controls. Hum Genet. 2012; 
131:1187–1195. [PubMed: 22362486] 
23. Sun YX, Yang J, Wang PY, et al. Cisplatin regulates SH-SY5Y cell growth through downregulation 
of BDNF via miR-16. Oncol Rep. 2013; 30:2343–2349. [PubMed: 24026226] 
24. Jaboin J, Hong A, Kim CJ, et al. Cisplatin-induced cytotoxicity is blocked by brain-derived 
neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett. 
2003; 193:109–114. [PubMed: 12691830] 
25. Connor B, Young D, Yan Q, et al. Brain-derived neurotrophic factor is reduced in Alzheimer’s 
disease. Mol Brain Res. 1997; 49(1):71–81. [PubMed: 9387865] 
26. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-
dependent secretion of BDNF and human memory and hippocampal function. Cell. 2017; 
112:257–269.
27. Silverman DHS, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia 
activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer 
Res Treat. 2007; 103:303–311. [PubMed: 17009108] 
Pearre and Bota Page 10
Expert Rev Qual Life Cancer Care. Author manuscript; available in PMC 2019 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Wang X, Walitt B, Saligan L, et al. Chemobrain: a critical review and causal hypothesis of link 
between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2016; 
8:583–592.
29. Tangpong J, Cole MP, Sultana R, et al. Adriamycin-induced, TNF-α-mediated central nervous 
system toxicity. Neurobiol Dis. 2006; 23:127–139. [PubMed: 16697651] 
30. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and 
TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with 
paclitaxel. Int J Gynecol Cancer. 2000; 10:33–41.Accessed 2017 Jul 30
31. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due 
to a shared biologic mechanism? Cancer. 2003; 97:2919–2925. [PubMed: 12767108] 
32. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. 
Science. 2003; :302.doi: 10.1126/science.1088417
33. Chen Y, Patel SK, Blum E, et al. Full-intensity transplantation and short telomeres increase the risk 
of cognitive impairment after allogeneic hematopoietic cell transplantation – results of a 
prospective longitudinal study. Blood. 2013; 122:913.
34. Brown RT, Madan-Swain A, Walco GA, et al. Cognitive and academic late effects among children 
previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J 
Pediatr Psychol. 1998; 23:333–340. [PubMed: 9782681] 
35. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical 
cancer. N Engl J Med. 2014; 370:734–743. [PubMed: 24552320] 
36. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for 
platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J 
Clin Oncol. 2014; 32:1302–1308. [PubMed: 24637997] 
37•. Nolen SC, Lee B, Shantharam S, et al. The effects of sequential treatments on hippocampal 
volumes in malignant glioma patients. J Neurooncol. 2016; 129:433–441. DOI: 10.1007/
s11060-016-2188-8 [PubMed: 27393350] 
38. Shaw EG, Rosdhal R, RBD, et al. Phase II study of donepezil in irradiated brain tumor patients: 
effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006; 24:1415–1420. 
[PubMed: 16549835] 
39. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual 
memory deficits in a mouse model of alzheimer’s disease. Neuropsychopharmacology. 2009; 
35:870–880. DOI: 10.1038/npp.2009.197 [PubMed: 20010553] 
40. Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer 
survivors. Cancer. 2010; 115:2605–2616. DOI: 10.1002/cncr.24287
41. Lundorff LE, Jonsson BHSP. Modafinil for attentional and psychomotor dysfunction in advanced 
cancer: A double-blind, randomised, cross-over trial. Palliat Med. 2009; 23:731–738. DOI: 
10.1177/0269216309106872 [PubMed: 19648224] 
42. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, 
mood, and function of brain tumor patients. J Clin Oncol. 1998; 16:2522–2527. DOI: 10.1200/
JCO.1998.16.7.2522 [PubMed: 9667273] 
43. Lawrence JA, Griffin L, Balcueva EP, et al. A study of donepezil in female breast cancer survivors 
with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer 
Surviv. 2016; 10:176–184. [PubMed: 26130292] 
44. DeLong R, Friedman H, Friedman N, et al. Methylphenidate in neuropsychological sequelae of 
radiotherapy and chemotherapy of childhood brain tumors and leukemia. J Child Neurol. 1992; 
7:462–463. [PubMed: 1469256] 
45. Levkovitz Y, Alpert JE, Brintz CE, et al. Effects of S-adenosylmethionine augmentation of 
serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J 
Affect Disord. 2012; 136:1174–1178. [PubMed: 21911258] 
46. Graff J, Rei D, Guan J-S, et al. An epigenetic blockade of cognitive functions in the 
neurodegenerating brain. Nature. 2012; 483:222–226. [PubMed: 22388814] 
47. Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-
related cognitive change. Psychooncology. 2007; 16:772–777. [PubMed: 17152119] 
Pearre and Bota Page 11
Expert Rev Qual Life Cancer Care. Author manuscript; available in PMC 2019 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
48. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-
induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical 
Oncology clinical practice guideline. J Clin Oncol. 2014; 32:1941–1967. [PubMed: 24733808] 
49. Cicerone KD, Dahlberg C, Kalmar K, et al. Evidence-based cognitive rehabilitation: 
recommendations for clinical practice. Arch Phys Med Rehabil. 2000; 81:1596–1615. [PubMed: 
11128897] 
50. Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a 
randomized controlled trial. Breast Cancer Res Treat. 2012; 135:799–809. DOI: 10.1007/
s10549-012-2210-6 [PubMed: 22918524] 
51. Devine JM, Zafonte RD. Physical exercise and cognitive recovery in acquired brain injury: a 
review of the literature. PM&R. 2009; 1:560–575. [PubMed: 19627946] 
52. Galantino ML, Greene L, Daniels L, et al. Longitudinal impact of yoga on chemotherapy-related 
cognitive impairment and quality of life in women with early stage breast cancer: a case series. J 
Sci Healing. 2012; 8:127–135.
53. Kesler S, Ph D, et al. YOCAS©® Yoga reduces self-reported memory difficulty in cancer survivors 
in a nationwide randomized clinical trial: investigating relationships between memory and sleep. 
Integr Cancer Ther. 2016; 15:263–271. [PubMed: 26621521] 
54. Wang Z, Nie B, Li D, et al. Effect of acupuncture in mild cognitive impairment and Alzheimer 
disease: a functional MRI study. PLoS One. 2012; 7:1–13.
55. Ling Z, Zhong Z, Jiao H. Electroacupuncture on the head points for improving gnosia in patients 
with vascular dementia. J Tradit Chinese Med. 2009; 29:29–34. DOI: 10.1016/
S0254-6272(09)60027-3
56. Amritanshu RR, Rao RM, Nagaratna R, et al. Effect of long-term yoga practice on psychological 
outcomes in breast cancer survivors. Indian J Palliat Care. 2017; 23:231–236. [PubMed: 
28827924] 
57••. Janelsins MC, Peppone LJ, Heckler CE, et al. YOCAS©® yoga reduces self-reported memory 
difficulty in cancer survivors in a nationwide randomized clinical trial: investigating relationships 
between memory and sleep. Integr Cancer Ther. 2016; 15:263–271. DOI: 
10.1177/1534735415617021 [PubMed: 26621521] 
58. Rao RM, Raghuram N, Nagendra HR, et al. Effects of a yoga program on mood states, quality of 
life, and toxicity in breast cancer patients receiving conventional treatment: a randomized 
controlled trial. Indian J Palliat Care. 2017; 23:237–246. [PubMed: 28827925] 
59. Craig CD, Monk BJ, Farley JH, et al. Cognitive impairment in gynecologic cancers: a systematic 
review of current approaches to diagnosis and treatment. Support Care Cancer. 2014; 22:279–287. 
[PubMed: 24212261] 
60. Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related 
cognitive change: results of a waitlist control trial. Psychooncology. 2012; 21:176–186. [PubMed: 
22271538] 
61. Lange, M, Joly, F. Cognitive function during and after treatment in elderly ovarian cancer patients. 
In: Freyer, G, editorOvarian cancer in elderly patients. Cham: Springer International Publishing; 
2016. 11–22. 
Pearre and Bota Page 12
Expert Rev Qual Life Cancer Care. Author manuscript; available in PMC 2019 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Key issues
• Chemotherapy-related cognitive decline (CRCD) has been shown in multiple 
studies to affect women suffering from gynecologic cancers. Women with 
cognitive decline before a cancer diagnosis are at a higher risk for developing 
CRCD.
• Cancer, in itself, may cause a variable amount of cognitive decline, 
confounding the role chemotherapy plays in accelerating this decline. Other 
factors such as metastatic disease to the nervous system, age-related decline, 
and menopausal status need to be taken into account by providers when 
counseling patients regarding CRCD.
• Multiple mechanisms have been proposed for what causes CRCD however the 
underlying cause is still unknown.
• Promising trials in pharmacologic and behavioral interventions have shown 
that currently available, FDA-approved therapies for other cognitive diseases 
may hold promising results for CRCD. While some have shown inconsistent 
results in neurocognitive assessments, many have reported increased quality 
of life scores in patients.
• Referral to a neurologist whenever CRCD is reported or suspected is 
warranted to engage a multi-disciplinary approach in addressing this huge 
quality of life concern.
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Table 1
Select studies exploring various mechanisms of CRCD.
Research group Measurement Groups Results
Mayerhofer et al. [56] Decreased brain connectivity (EEG 
pre-and posttreatment)
Carboplatin and paclitaxel No differences seen
Kreukels et al. [57] Decreased brain connectivity (EEG 
in patients treated and nontreated 
controls 4 years following therapy)
Cyclophosphamide, epirubicin, 5-
fluorouracil or adjuvant high-dose 
cyclophosphamide, thiotepa, 
carboplatin
Decreased processing speeds in 
chemotherapy exposed group
Penson et al. [30] Inflammatory markers Carboplatin and Paclitaxel in ovarian 
cancer patients
Increased IL-6
Hess et al. [58] Cognition tested through online 
modules at baseline, after 3 and 6 
cycles of chemotherapy.
Patients with ovarian cancer treated 
with carboplatin and paclitaxel
Decreased cognitive function over 
treatment course
Hensley et al. [59] Objective quality of life and 
cognitive measurements
Carboplatin, Paclitaxel, and 
Gemcitabine
No impairment on objective 
measures
Ahles et al. [60] Brain structural changes seen on 
MRI
Breast cancer patients Structural imaging correlates with 
poor performance on cognitive tests
Deprez et al. [61] Structural changes correlated with 
cognitive changes
Breast cancer patients who have 
undergone chemotherapy
Slower fractional anisotropy
Hess et al. [14]. Web-based cognitive assessment 
and patient reported questionnaires
NRG Oncology/Gynecologic 
Oncology Group (GOG) study on 
patient receiving primary treatment of 
primary peritoneal, fallopian tube, or 
ovarian cancer
Patients experienced a decline in 
cognitive ability in at least one 
measured domain from baseline.
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